Blood tests for Alzheimer's disease moved from promising to practically useful at the Alzheimer's Association International Conference (AAIC) 2026, where new data showed they measurably sharpen diagnosis for people already showing memory or thinking problems. For someone with mild cognitive impairment (MCI) — a diagnosis meaning noticeable decline in memory or thinking that doesn't yet interfere with daily independence — the evidence supports using these tests to refine a doctor's diagnostic plan, not to replace it.
The distinction matters because AAIC 2026 also produced a second, easily confused finding: a blood marker predicting future decline in people who show no symptoms at all. That result, covered widely in headlines, describes a different population and a different use than the diagnostic studies. Readers with an MCI diagnosis need to know which evidence actually applies to them.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What AAIC 2026 Actually Showed About Diagnosis
- Why Not Every Blood Test Clears the Bar
- The Study on Healthy Adults Doesn't Apply to an MCI Diagnosis
- What This Means for Someone Already Diagnosed With MCI
- Frequently Asked Questions
What AAIC 2026 Actually Showed About Diagnosis
The most direct evidence comes from a large Swedish study presented at the conference. Researchers tracked 1,310 patients with MCI or dementia who were evaluated by 165 physicians across primary care and specialist settings. Before seeing blood-test results from PrecivityAD2, primary-care doctors diagnosed Alzheimer's correctly 65% of the time; after seeing the results, accuracy rose to 93%. Specialists improved too, from 74% to 89% accuracy, according to AAIC 2026 press materials reported by LabMedica. That jump wasn't cosmetic — seeing the blood-test result led primary-care clinicians to change their diagnosis in 30% of patients.
Lead author Sebastian Palmqvist noted the test's clearest practical value is ruling Alzheimer's out as a cause of symptoms, rather than confirming it on its own, per the same AAIC 2026 coverage. That framing matters for someone with MCI: a blood test is most useful for telling a doctor when Alzheimer's is unlikely, freeing up the diagnostic workup to look elsewhere. A separate AAIC 2026 trial reinforces the same pattern in specialist care. Researchers ran a randomized virtual trial with 142 US neurologists across 852 patient encounters, testing whether access to a blood test measuring p-tau217 and Aβ1-42 (two proteins tied to Alzheimer's brain changes) changed diagnostic behavior. Neurologists with access to the test agreed with each other more often on an early Alzheimer's diagnosis and relied less on confirmatory PET scans or spinal fluid testing, according to Practical Neurology's AAIC 2026 coverage.
Why Not Every Blood Test Clears the Bar
The Alzheimer's Association's clinical practice guideline on blood-based biomarkers sets specific accuracy thresholds before a test should guide care. A test used as a first-pass triage tool needs at least 90% sensitivity (catching true cases) and 75% specificity (correctly clearing people without the disease); a test meant to substitute for PET or spinal fluid testing needs 90% on both measures, per the Alzheimer's Association guideline.
The guideline panel was explicit that many commercially available blood tests don't meet those thresholds, particularly when a lab reports a single yes/no cutoff instead of a more nuanced result. Results need to be read alongside a patient's overall likelihood of having Alzheimer's pathology going into the test — not treated as a verdict on their own, according to the Alzheimer's Association guideline hub. A person with MCI considering a blood test should ask their clinician which test is being used and whether it meets these accuracy standards, since test quality varies.
The Study on Healthy Adults Doesn't Apply to an MCI Diagnosis
A widely covered AAIC 2026 study followed nearly 2,700 adults with no cognitive symptoms, averaging 70 years old, and found that those with very high levels of p-tau217 had roughly a 78% chance of developing cognitive impairment — MCI or a mild dementia rating — within ten years, per Alzheimer Europe's summary of the JAMA findings. That statistic describes risk prediction in people who are symptom-free today, not a diagnostic tool for someone already diagnosed with MCI.
Trade coverage of the conference notes that p-tau217 blood tests are currently indicated only for people who already have symptoms of Alzheimer's disease; using the marker to predict future risk in symptom-free adults remains an investigational research use, not a cleared clinical application, according to NeurologyLive's AAIC 2026 coverage. A reader with MCI who sees headlines about this 78% figure should recognize it comes from a different population answering a different question.
What This Means for Someone Already Diagnosed With MCI
For a person already evaluated for MCI in a memory clinic or by a primary care doctor, the AAIC 2026 evidence supports a specific, limited role for blood testing: it can sharpen the diagnostic plan a doctor is already building, especially by helping rule out Alzheimer's as the cause of symptoms. The Alzheimer's Association's guideline frames the test as an adjunct to clinical evaluation — not a standalone diagnosis of Alzheimer's as the reason behind an MCI diagnosis, per the guideline.
In practice, that means a positive or negative blood-test result should prompt a conversation with the ordering clinician about what it changes, not stand in as a final answer. Useful questions to raise: The Swedish and US neurologist studies both show blood testing changing what doctors do next — ordering fewer confirmatory scans, or changing a diagnosis outright — which is the practical benefit an MCI patient should expect: a faster, more confident path through the diagnostic process, not a replacement for it.
- Which specific blood test was used, and does it meet the triage or PET/CSF-substitute accuracy thresholds set by the Alzheimer's Association?
- Does this result rule Alzheimer's in, rule it out, or leave the question open — and what's the next step either way?
- Is a PET scan or spinal fluid test still needed to confirm the result, or does this result stand on its own for this stage of the workup?
- Was the result interpreted together with symptoms, history, and other testing, or in isolation?
Frequently Asked Questions
Can a blood test alone confirm whether MCI is caused by Alzheimer's disease?
No. The Alzheimer's Association's guideline treats blood-based biomarker results as an adjunct to clinical evaluation, to be read alongside a patient's overall likelihood of Alzheimer's pathology, not as a standalone diagnosis.
Does the 78% ten-year risk figure from AAIC 2026 apply to people already diagnosed with MCI?
No. That figure comes from a study of nearly 2,700 cognitively unimpaired adults and describes future risk in people without symptoms, not a diagnostic measure for someone who already has MCI.
What should someone with MCI ask their doctor about a blood test result?
Ask which specific test was used, whether it meets the Alzheimer's Association's accuracy thresholds, whether the result rules Alzheimer's in or out, and whether a PET scan or spinal fluid test is still needed to confirm it.
You Might Also Like
- The AAIC 2026 Swedish Real-World Blood Test Study: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- Vitamin Supplements in the 2026 WHO Dementia Guideline: How the Advice Compares With Common Online Claims for People With Mild Cognitive Impairment
- NIA’s 2026 Food Insecurity and Cognitive Health Workshop: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
